Global Cancer Immunotherapy Market Insights and Forecast to 2028

Cancer Immunotherapy Market Outlook 2028

The global Cancer Immunotherapy market size is projected to reach USD 135140 million by 2028, from USD 75950 million in 2021, at a CAGR of 8.1% during 2022-2028.

Major Trends in Cancer Immunotherapy Market 

Key drivers of the Cancer Immunotherapy market include the growing prevalence of cancer cases and increasing awareness regarding cancer immunotherapies.

The technological advancements in cancer treatment and newer drug usage such as checkpoint inhibitors will fuel the growth of the cancer immunotherapy market during the forecast period. 

The increasing R&D initiatives into the effectiveness of monoclonal antibodies as alternative therapy will propel market growth in the coming years. However, strict government regulations and high product development costs will hamper the market demand. While Lung Cancer segment is altered to an % CAGR throughout this forecast period.

Cancer Immunotherapy

Immunotherapy, also called biologic therapy, is a type of cancer treatment that boosts the body's natural defenses to fight cancer.

Trends Influencing Global Cancer Immunotherapy Market 

Worldwide surge in cancer-related problems

As per WHO about 10 million or 1 in six deaths globally happened due to cancer in 2020. It is a serious public health challenge with the burden expected to rise in the coming years. Lung cancers are the most common type. Cancer immunotherapy has emerged as a way of targeted therapy treatment sessions with improved efficacy and safety standards. It helps in the precise targeting of the cancer cells by boosting the immune system. This is going to bolster the cancer immunotherapy market during the forecast period.

Technological innovations 

Cancer treatment is going through a transition pace due to fast technology changes. Personalized medicine has taken the center stage along with the use of checkpoint inhibitors. Targeted cancer vaccines are being developed that are based on mRNA molecules. These molecules basically instruct immune cells to make proteins against cancer antigens for boosting immunity. Comparing the DNA sequences of healthy and malignant cells enables a deep understanding of the type of cancer mutations that will trigger a strong response from the immune system. The early clinical trials show great promise. This in turn will create lucrative opportunities for the cancer immunotherapy market in the future. The vaccine technology is expected to be cheaper which will further boost the market demand. 

Monoclonal Antibody Research 

MAbs are artificially grown antibodies in laboratories. They are used across the world for treating cancers. Monoclonal antibodies either kill cancer cells directly by triggering the immune system or act on the proteins in immune cells. They can be used in a single or in a variety of ways. Moreover, R&D activities are being carried out for developing conjugated, naked antigen binding or biospecific antibodies. This will create alternative treatment options thereby driving the growth of the cancer immunotherapy market during the forecast period. 

Tough regulations and costly feature

The ongoing clinical trials and research is being carried out under government supervision. This makes it hard for industry players to enter the market. In addition to it, the cost of cancer immunotherapy drugs is expensive and provides an extra burden on the overall healthcare system. These factors will restrict the growth of the cancer immunotherapy market during the reviewed period. 

Cancer Immunotherapy Market Size and Share

China Cancer Immunotherapy market size is valued at US$ million in 2021, while the North America and Europe Cancer Immunotherapy are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period.
As for the Europe Cancer Immunotherapy landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.

Based on type, the monoclonal antibodies segment will grow the highest in the cancer immunotherapy market share as MAbs are extensively used as therapies for treating various types of cancer.

Based on application, lung cancer will maintain dominance in the cancer immunotherapy market share owing to the growing burden of lung cancer diseases and the need for early therapy.

Based on region, North America is expected to provide lucrative opportunities for growth in the cancer immunotherapy market share due to rising cancer cases and increasing healthcare spending for treatment along with advanced technologies.

Cancer Immunotherapy Market Insights

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cancer Immunotherapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cancer Immunotherapy market.

Cancer Immunotherapy Market Segment and Scope

Cancer Immunotherapy market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Cancer Immunotherapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Cancer Immunotherapy Market Segment By Type

• Monoclonal Antibodies
• Immune Checkpoint Inhibitors
• Immune System Modulators
• Cancer Vaccines

Cancer Immunotherapy Market Segment By Application

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Melanoma
• Prostate Cancer
• Others

By Company

• Amgen
• AstraZeneca
• Roche
• Bayer
• Bristol-Myers Squibb
• Eli Lilly
• Merck
• Novartis
• Pfizer

By Region

• North America
• United States
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Nordic Countries
• Rest of Europe
• Asia-Pacific
• China
• Japan
• South Korea
• Southeast Asia
• India
• Australia
• Rest of Asia
• Latin America
• Mexico
• Brazil
• Rest of Latin America
• Middle East & Africa
• Turkey
• Saudi Arabia
• UAE
• Rest of MEA